中华医学杂志
中華醫學雜誌
중화의학잡지
National Medical Journal of China
2012年
42期
2984-2987
,共4页
郑振东%屈淑贤%刘永叶%郝辉%章国晶%谢晓冬
鄭振東%屈淑賢%劉永葉%郝輝%章國晶%謝曉鼕
정진동%굴숙현%류영협%학휘%장국정%사효동
肾肿瘤%抗肿瘤联合化疗方案%分子靶向治疗%临床对照试验
腎腫瘤%抗腫瘤聯閤化療方案%分子靶嚮治療%臨床對照試驗
신종류%항종류연합화료방안%분자파향치료%림상대조시험
Kidney neoplasms%Antineoplastic combined chemotherapy protocols%Molecular targeted therapy%Controlled clinical trial
目的 研究不同治疗方法对晚期肾癌患者一线治疗的疗效.方法 通过前瞻性对照研究方法将2006-2011年收治的82例晚期肾癌患者分为3组,分别给予吉西他滨联合白细胞介素2(IL-2)(A组,n=30)、奥沙利铂联合卡培他滨化疗(B组,n=30)及单药索拉非尼治疗(C组,n=22).结果 76例患者有完整的数据资料,A、B、C组治疗总有效率分别为39.3％(11/28)、37.0％(10/27)、38.1％(8/21),差异无统计学意义(x2=0.029;P =0.986)；中位疾病无进展期(PFS)分别为9.1个月(95％ CI:7.9 ～ 10.3个月)、7.5个月(95％CI:5.5 ～9.5个月)、10.9个月(95％ CI:10.5～11.3个月),差异有统计学意义(P =0.013)；日均治疗费用分别为人民币490、498、501元,差异无统计学意义(P=1.240).因毒性反应退出研究:A组2例,B组3例,C组0例.结论 对于不能一线选择索拉非尼的晚期肾癌患者,奥沙利铂联合卡培他滨化疗可取得与吉西他滨联合IL-2治疗相似的早期疗效,而且在患者耐受度上也相似.
目的 研究不同治療方法對晚期腎癌患者一線治療的療效.方法 通過前瞻性對照研究方法將2006-2011年收治的82例晚期腎癌患者分為3組,分彆給予吉西他濱聯閤白細胞介素2(IL-2)(A組,n=30)、奧沙利鉑聯閤卡培他濱化療(B組,n=30)及單藥索拉非尼治療(C組,n=22).結果 76例患者有完整的數據資料,A、B、C組治療總有效率分彆為39.3％(11/28)、37.0％(10/27)、38.1％(8/21),差異無統計學意義(x2=0.029;P =0.986)；中位疾病無進展期(PFS)分彆為9.1箇月(95％ CI:7.9 ～ 10.3箇月)、7.5箇月(95％CI:5.5 ～9.5箇月)、10.9箇月(95％ CI:10.5～11.3箇月),差異有統計學意義(P =0.013)；日均治療費用分彆為人民幣490、498、501元,差異無統計學意義(P=1.240).因毒性反應退齣研究:A組2例,B組3例,C組0例.結論 對于不能一線選擇索拉非尼的晚期腎癌患者,奧沙利鉑聯閤卡培他濱化療可取得與吉西他濱聯閤IL-2治療相似的早期療效,而且在患者耐受度上也相似.
목적 연구불동치료방법대만기신암환자일선치료적료효.방법 통과전첨성대조연구방법장2006-2011년수치적82례만기신암환자분위3조,분별급여길서타빈연합백세포개소2(IL-2)(A조,n=30)、오사리박연합잡배타빈화료(B조,n=30)급단약색랍비니치료(C조,n=22).결과 76례환자유완정적수거자료,A、B、C조치료총유효솔분별위39.3％(11/28)、37.0％(10/27)、38.1％(8/21),차이무통계학의의(x2=0.029;P =0.986)；중위질병무진전기(PFS)분별위9.1개월(95％ CI:7.9 ～ 10.3개월)、7.5개월(95％CI:5.5 ～9.5개월)、10.9개월(95％ CI:10.5～11.3개월),차이유통계학의의(P =0.013)；일균치료비용분별위인민폐490、498、501원,차이무통계학의의(P=1.240).인독성반응퇴출연구:A조2례,B조3례,C조0례.결론 대우불능일선선택색랍비니적만기신암환자,오사리박연합잡배타빈화료가취득여길서타빈연합IL-2치료상사적조기료효,이차재환자내수도상야상사.
Objective To estimate the efficacies of different first-line treatments for advanced stage kidney cancer.Methods For this observation controlled trial,a total of 82 cases with advanced stage kidney cancer from 2006 to 2011 were recruited.They were divided into 3 groups and accepted gemcitabine plus interleukin-2 (IL-2) (Group A),oxaliplatin plus capecitabine (Group B) or sorafenib alone (Group C).Results Among them,76 patients had complete data.The overall response rates of A-C groups were 39.3％ (11/28),37.0％ (10/27) and 38.1％ (8/21) respectively.And there was no significant difference (x2 =0.029,P =0.986).And their progression-free survival (PFS) rates were 9.1 (95％ CI:7.9-10.3),7.5 (95 ％ CI:5.5-9.5) and 10.9 (95 ％ CI:10.5-11.3) months respectively.And there were significant differences (P =0.013).Average daily treatment costs were 490,498 and 501 Chinese yuan respectively.And there was no significant difference (P =1.240).Because of toxicity,2 and 3 cases withdrew in Groups A and B respectively.Conclusion Gemcitabine plus IL-2 and oxaliplatin plus capecitabine have similar early efficacies and tolerance profiles for the patients who can not accept sorafenib as first-line treatment.
